Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

Recruiting

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(1 site)

China

1# Banshan East Rd. Zhejiang cancer hospital, Hangzhou, Zhejiang